Editas Medicine shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $13 to $15.
Portfolio Pulse from Benzinga Newsdesk
Editas Medicine shares are trading higher following an upgrade from B of A Securities, which raised the stock rating from Neutral to Buy and increased the price target from $13 to $15.
August 08, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $13 to $15.
The upgrade from a major financial institution like B of A Securities and the increase in the price target are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100